Galderma presents Nemluvio data: Galderma stock trades at EUR 172.98 versus EUR 174.35

Published on 10/08/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 24.60 percent to USD 3.10 billion. Galderma stock costs EUR 172.98 on October 8, 2026 versus EUR 174.35 at Tradegate.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock was trading at EUR 172.98 at Lang & Schwarz on October 8, 2026 at 11:00 a.m. CEST, versus the EUR 174.35 Tradegate close of October 7, 2026. On October 8, Morningstar reported that Galderma presented new three-year Nemluvio data at the Fall Clinical Dermatology Conference.

Nemluvio data deepen the pipeline case

The data came from the ARCADIA long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis. Among 295 early responders assessed at Week 16, 76 percent had clear or almost clear skin at Week 152, while 80 percent achieved at least a 90 percent improvement in disease severity, according to Morningstar.

The same release said 80 percent of the Week 152 group reached an itch-free or nearly itch-free state. For Galderma, the figures extend the evidence base for Nemluvio across atopic dermatitis and prurigo nodularis while the product continues its global launch.

First-half growth supports guidance

Galderma's first-half 2026 net sales reached USD 3.10 billion, up 24.60 percent year over year at constant currency. The company reported core EBITDA of USD 802.00 million and a core EBITDA margin of 25.60 percent for the period, according to the Yahoo Finance transcript.

The first-half sales increase compares with Galderma's raised full-year net sales growth guidance of 19.00 percent to 21.00 percent at constant currency, up from the previous 17.00 percent to 20.00 percent range. Core earnings per share rose 68.50 percent year over year to USD 2.34, giving the growth story a measurable profit component.

Stock sits below its yearly high

The SIX-listed stock had a 52-week range of CHF 134.70 to CHF 188.25 as of October 8, 2026, while market capitalization stood at CHF 37.7 billion. The current Swiss-franc quote was CHF 161.60 at 10:44 a.m. CEST, separate from the euro reference price used for German-market investors.

The Lang & Schwarz price of EUR 172.98 was 0.79 percent below the EUR 174.35 Tradegate close of October 7, 2026. That modest euro-market gap leaves the clinical data and the raised growth outlook as the central operating reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.